GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of FGEN
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Wednesday for FibroGen
(Updated on Apr 17, 2024)

Sell candidate since Apr 03, 2024 Loss -13.61% PDF

The FibroGen stock price fell by -2.31% on the last day (Wednesday, 17th Apr 2024) from $1.30 to $1.27. During the last trading day the stock fluctuated 7.26% from a day low at $1.24 to a day high of $1.33. The price has fallen in 6 of the last 10 days and is down by -13.61% for this period. Volume has increased on the last day by 187 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 1 million shares were bought and sold for approximately $1.31 million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $1.04 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 10.51% during the next 3 months and, with a 90% probability hold a price between $1.15 and $3.25 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

FGEN Signals & Forecast

There are few to no technical positive signals at the moment. The FibroGen stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.35 and $1.91. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, February 09, 2024, and so far it has fallen -53.48%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). FibroGen gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

Support, Risk & Stop-loss for FibroGen stock

On the downside, the stock finds support just below today's level from accumulated volume at $1.10 and $0.97. With no support from accumulated volume below today's level the risk is increased, as a drop below the support at $0.97 may give a huge drop in the stock price.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.0900 between high and low, or 7.26%. For the last week, the stock has had daily average volatility of 8.80%.

FibroGen is oversold on RSI14 (11). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (FGEN) For The Upcoming Trading Day Of Thursday 18th

For the upcoming trading day on Thursday, 18th we expect FibroGen to open at $1.28, and during the day (based on 14 day Average True Range), to move between $1.03 and $1.51, which gives a possible trading interval of +/-$0.235 (+/-18.52%) up or down from last closing price. If FibroGen takes out the full calculated possible swing range there will be an estimated 37.04% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $1.30 (2.36%) than the support at $1.10 (13.39%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is FibroGen stock A Buy?

The FibroGen stock holds several negative signals and despite the positive trend, we believe FibroGen will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -4.115 Sell Candidate Unchanged

Predicted Opening Price for FibroGen of Thursday, April 18, 2024

Fair opening price April 18, 2024 Current price
$1.28 ( 0.787%) $1.27

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for FGEN

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.37 7.87 %
R2 1.34 5.17 %
R1 1.31 3.49 %
Current price: 1.27
Support S1 1.25 -1.92 %
S2 1.22 -3.59 %
S3 1.19 -6.30 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.58 24.41 %
R2 1.47 15.75 %
R1 1.30 2.36 %
Current price 1.27
Support S1 1.10 -13.39%
S2 0.97 -23.60%
S3 0 .

FAQ

What is the symbol for FibroGen Stock and on which exchange is it traded?
The symbol for FibroGen is FGEN and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell FibroGen Stock?
The FibroGen stock holds several negative signals and despite the positive trend, we believe FibroGen will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy FibroGen Stock?
FibroGen Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy FibroGen Stock.

What's the current price of FibroGen Stock?
As of the end of day on the 2024-04-17, the price of an FibroGen (FGEN) share was $1.27.

What is the 52-week high and low for FibroGen Stock?
The 52-week high for FibroGen Stock is $20.90 and the 52-week low is $0.335.

What is the market capitalization of FibroGen Stock?
As of the 2024-04-17, the market capitalization of FibroGen is 125.439M.

When is the next earnings date for FibroGen?
The upcoming earnings date for FibroGen is May 13, 2024.
Click to get the best stock tips daily for free!

About FibroGen

FibroGen FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China ... FGEN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT